IM-UNITI: 3 Year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease.

Hanauer, Stephen B, Sandborn, William J, Feagan, Brian G, Gasink, Christopher, Jacobstein, Douglas, Zou, Bin, Johanns, Jewel, Adedokun, Omoniyi J, Sands, Bruce E, Rutgeerts, Paul, de Villiers, Willem J S, Colombel, Jean-Frédéric and Ghosh, Subrata (2019) IM-UNITI: 3 Year Efficacy, Safety, and Immunogenicity of Ustekinumab Treatment of Crohn's Disease. Journal of Crohn's & colitis. ISSN 1876-4479.

Full text not available from this repository.

Abstract

BACKGROUND AND AIMS

Following induction/maintenance treatment in the UNITI/IM-UNITI studies of ustekinumab for Crohn's disease, patients entered a long-term extension for up to 5 years from induction. Efficacy through 152 and safety through 156 weeks are reported.

METHODS

At IM-UNITI Week 44, 567 ustekinumab-treated patients entered the long-term extension and continued to receive blinded subcutaneous ustekinumab on their assigned dose interval, without any subsequent dose adjustment. Placebo-treated patients discontinued after study unblinding (after IM-UNITI Week 44 analyses). Efficacy data in the LTE were collected every 12 weeks (q12w) prior to unblinding and then at q12w/q8w dosing visits.

RESULTS

Through Week 156, 29.6% of ustekinumab-treated patients discontinued. In an intent-to-treat analysis of randomized patients from IM-UNITI Week 0-152, 38.0% of ustekinumab induction responders receiving drug q12w and 43.0% q8w were in remission at Week 152. Among patients entering the long-term extension in their original randomized groups, 61.9% of q12w and 69.5% of q8w patients were in remission at Week 152. Across all ustekinumab-treated patients (randomized and non-randomized) entering the long-term extension, remission rates at Week 152 were 56.3% and 55.1% for q12w and q8w, respectively.

CONCLUSION

Continued treatment with subcutaneous ustekinumab maintained clinical response and remission through 3 years in a majority of patients who responded to induction therapy and was well-tolerated. ClinicalTrials.gov number NCT01369355.

Item Type: Article
Subjects: WI Digestive system. Gastroenterology
Divisions: Planned IP Care > Gastroentrology
Depositing User: Miss Emily Johnson
Date Deposited: 10 Jun 2019 10:39
Last Modified: 10 Jun 2019 10:39
URI: http://www.repository.uhblibrary.co.uk/id/eprint/2148

Actions (login required)

View Item View Item